MedTrace Logo

Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder

NCT00139594 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2017-03-28

No results posted yet for this study

Summary

This extension study is designed to assess the long-tem tolerability and safety of licarbazepine in patients who completed the 6-week double-blind study CLIC477D2303.

Conditions

Interventions

DRUG

licarbazepine

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • United States
  • Austria
  • Canada
  • Colombia
  • Czechia
  • Germany
  • Guatemala
  • Peru
  • Russia
  • Slovakia
  • South Africa
  • Ukraine
  • Venezuela

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00139594 on ClinicalTrials.gov